RNA-sequencing of human glioblastoma resected tissue before and after inoculation with G207, an oncolytic herpes simplex virus; tissues from a Phase Ib clinical trial

We have previously developed the use of genetically engineered herpes simplex virus type 1 ("G207") for the experimental treatment of malignant glioma (PMID: 18957964). We demonstrated that G207 propagates in and kills nervous system tumor cells with little to no evidence of viral encephalitis. Here, six adult patients with recurrent glioblastoma were recruited onto a phase Ib clinical trial to test G207 safety and efficacy in anti-tumor response. We obtained resected tumor tissue before and after (within 2-5 days) inoculation with G207. RNA was extracted from all tissues and subject to library preparation for RNA sequencing on Illumina instrumentation. Gene expression analysis of recurrent glioblastoma before and after inoculation with oncolytic herpes simplex virus G207.